The burgeoning iPSC product market lures major industry competitors with double-digit growth and massive change in 2013.
Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington’s Chorea, Parkinson’s Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.
Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.
Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells.
While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been issues along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.
Furthermore, the past twelve months have been a time of massive change for the industry. 2013 was the first year in which clinical research involving transplant of iPSCs into humans was initiated, with Masayo Takahashi of the RIKEN Center in Japan investigating the safety of iPSC-derived cell sheets in patients with macular degeneration. In another landmark event, Cellular Dynamics International (CDI) went public in July 2013 with a offering that raised $43 million dollars for the company, securing the company's position as the global leader in producing high-quality human iPSCs and differentiated cells in industrial quantities. In March of 2013, Celullar Dynamics International and the Coriell Institute for Medical Research announced receiving multi-million dollars grants from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors, a result that will create the world’s largest human iPSC bank.
2013 represents a major year for advances in clinical research applications, production and differentiation technologies, and biobanking of iPSCs. It is clear that iPSCs are a vital research trend within the scientific community.
Continued research and experimentation has resulted in numerous advances over the last few years. In one example, the University of Michigan announced in “Circulation Research” (2012) that they had developed innovative methods for use of induced pluripotent stem cells derived from skin biopsies to create cardiac muscle cells. This accomplishment quickly fueled other research into the use of iPSCs for the reversal and repair of diseased heart tissue.
Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders. Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industries join with the scientific community to develop safe and efficient methods of iPSC production. With sustained research and experimentation, established guidelines for effective production of iPSCs will be commonplace.
In summary, induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases.
Market Metrics - iPSC Research Products:
For this reason a large and thriving research products market has grown into existence for the cell type. The number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% for the past five years. In addition, 22% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community.
A distinctive feature of this report is an end-user survey of 274 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as their core research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. They can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
Remember, to benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.
Key Findings Include:
- Charts, Timelines, and Financials for the iPSC Research Product Market
- Trends for iPSC Grants, Scientific Publications, and Patents
- 5-Year Market Size Projections (2014-2018)
- Competitive Environment Analysis, including Market Share by Competitor
- Preferred Species for iPSC Research
- iPSC Product Categories (Breakdown of Market Share by Each)
- Consumer Behavioral Patterns and Preferred Providers
- Crucial Trends and Unmet Market Needs
- “Tested Sentences” for Selling to iPSC Scientists
- Breakdown of the Marketing Methods Used by Industry Participants
- End-User Survey of iPSC Researchers (131 U.S. / 143 International)
In summary, this is a must-read industry report for research supply companies to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the marketplace, and take advantage of crucial iPSC trends. Claim this report now to profit from this expanding market - or your competition will.